文献速递乳腺癌

晚期雌激素受体阳性乳腺癌中PI3K-AKT与mTOR通路的最佳靶向策略

Optimal targeting of PI3K-AKT and mTOR in advanced oestrogen receptor-positive breast cancer.
PubMed 文献 · Lancet Oncol · 2024-01-01

综述总结晚期雌激素受体阳性乳腺癌中PI3K-AKT与mTOR通路靶向治疗,涵盖PI3K抑制剂阿培利司用于PIK3CA突变肿瘤、AKT抑制剂卡匹色替用于PIK3CA/AKT1/PTEN改变肿瘤及mTOR抑制剂依维莫司(不限突变状态),并讨论CDK4/6抑制剂进展后的最佳序贯策略。

要点

  • 阿培利司用于PIK3CA突变晚期ER阳性乳腺癌,卡匹色替用于PIK3CA/AKT1/PTEN改变者,依维莫司不限突变状态。
  • 不同抑制剂的选择需结合个体患者突变状态与用药时机。
  • 综述讨论尤其CDK4/6抑制剂进展后靶向治疗的优化序贯策略。

核心结论

  • 综述总结PI3K-AKT与mTOR通路及三种抑制剂的认识,并讨论临床最佳序贯策略,尤其CDK4/6抑制剂进展后。

研究设计与样本

  • 综述,检索范围与样本量原文未报告。

主要发现

  • PI3K-AKT与mTOR通路是乳腺癌中最常激活的通路之一,在肿瘤发病机制中起关键作用。
  • 获批用于ER阳性晚期乳腺癌的靶向药包括PI3K抑制剂阿培利司(用于PIK3CA突变肿瘤)、AKT抑制剂卡匹色替(用于PIK3CA、AKT1或PTEN改变肿瘤)和mTOR抑制剂依维莫司(不限突变状态)。

关键数值与推荐

  • 阿培利司用于PIK3CA突变肿瘤。
  • 卡匹色替用于PIK3CA、AKT1或PTEN改变的肿瘤。
  • 依维莫司不限突变状态使用。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

The growing availability of targeted therapies for patients with advanced oestrogen receptor-positive breast cancer has improved survival, but there remains much to learn about the optimal management of these patients. The PI3K-AKT and mTOR pathways are among the most commonly activated pathways in breast cancer, whose crucial role in the pathogenesis of this tumour type has spurred major efforts to target this pathway at specific kinase hubs. Approvals for oestrogen receptor-positive advanced breast cancer include the PI3K inhibitor alpelisib for PIK3CA-mutated tumours, the AKT inhibitor capivasertib for tumours with alterations in PIK3CA, AKT1, or PTEN, and the mTOR inhibitor everolimus, which is used irrespective of mutation status. The availability of different inhibitors leaves physicians with a potentially challenging decision over which of these therapies should be used for individual patients and when. In this Review, we present a comprehensive summary of our current understanding of the pathways and the three inhibitors and discuss strategies for the optimal sequencing of therapies in the clinic, particularly after progression on a CDK4/6 inhibitor.

来源:Lancet Oncol,查看原文。版权归原作者所有。

引用

  1. Browne IM, André F, Chandarlapaty S, et al. Optimal targeting of PI3K-AKT and mTOR in advanced oestrogen receptor-positive breast cancer. Lancet Oncol. 2024. PMID: 38547898. doi:10.1016/S1470-2045(23)00676-9

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。